Retour sur lavenir.net
   ACKERMANS V.HAAREN 284.800 € (-0,77 %)     AB INBEV 74.680 € (+1,22 %)     ARGENX SE 784.400 € (+0,33 %)     UMICORE 20.820 € (-2,25 %)     VASTNED 29.750 € (+0,34 %)     KBC ANCORA 80.900 € (+0,62 %)     IBA 16.760 € (+0,60 %)     KBC 117.250 € (-0,51 %)     ELIA GROUP 138.500 € (-0,86 %)     WDP 22.520 € (+1,08 %)     HOME INVEST BE. 19.300 € (-0,21 %)     AZELIS GROUP 9.910 € (-0,10 %)     WHAT'S COOKING GP 144.500 € (0,00 %)     EVS 27.700 € (-0,72 %)     SYENSQO 66.800 € (-0,30 %)     BPOST 1.552 € (-0,51 %)     TITAN S.A. 52.500 € (-1,50 %)     MONTEA 67.200 € (+1,66 %)     MELEXIS 76.400 € (-3,41 %)     GIMV 45.150 € (+2,03 %)     SHURGARD 25.750 € (+0,98 %)     CENERGY 23.300 € (-3,80 %)     KINEPOLIS GROUP 36.500 € (+2,38 %)     JENSEN-GROUP 84.200 € (+1,45 %)     ORANGE BELGIUM 21.500 € (0,00 %)     SIPEF 92.900 € (+0,32 %)     CIE BOIS SAUVAGE 302.000 € (0,00 %)     FLUXYS BELGIUM D 19.500 € (+0,26 %)     RETAIL ESTATES 70.100 € (+0,43 %)     ATENOR 1.690 € (-3,43 %)     FAGRON 23.800 € (-0,63 %)     ACCENTIS 0.026 € (-1,89 %)     BEKAERT 39.500 € (-1,86 %)     XIOR 26.700 € (+1,14 %)     WERELDHAVE BELGIUM 52.800 € (+0,76 %)     PROXIMUS 6.085 € (-0,33 %)     D'IETEREN GROUP 170.500 € (-1,73 %)     TINC 11.380 € (0,00 %)     SOFINA 220.200 € (+0,46 %)     ONWARD MEDICAL 2.640 € (+0,96 %)     ECONOCOM GROUP 1.515 € (+1,68 %)     GBL 78.950 € (-0,19 %)     RECTICEL 10.740 € (-1,10 %)     NYXOAH 1.530 € (+3,66 %)     AGEAS 69.750 € (+0,50 %)     AGFA-GEVAERT 0.423 € (-1,40 %)     COFINIMMO 84.500 € (+1,62 %)     CARE PROPERTY INV. 12.600 € (+0,48 %)     LOTUS BAKERIES 11 520.000 € (+0,88 %)     VGP 84.300 € (0,00 %)     VIOHALCO 19.320 € (-0,92 %)     BIOTALYS 3.120 € (-1,58 %)     ONTEX GROUP 2.525 € (+0,20 %)     TUBIZE-FIN 225.400 € (+2,55 %)     VAN DE VELDE 30.200 € (0,00 %)     CAMPINE 218.000 € (+1,87 %)     CMB.TECH 12.500 € (-4,87 %)     DECEUNINCK 2.220 € (0,00 %)     CELYAD ONCOLOGY 0.251 € (+0,40 %)     BREDERODE 104.600 € (+1,36 %)  
   NANOBIOTIX 31.080 € (+3,74 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     TOTALENERGIES 68.360 € (-1,31 %)     SERGEFERRARI GROUP 8.000 € (+2,56 %)     ADYEN 824.900 € (+0,37 %)     EXAIL TECHNOLOGIES 116.700 € (+25,28 %)     CAPGEMINI 89.680 € (+1,33 %)     SHELL PLC 33.700 € (-1,00 %)     BUREAU VERITAS 26.120 € (+0,66 %)     HERMES INTL 1 626.000 € (+0,77 %)     PHILIPS KON 23.890 € (-0,17 %)     SANOFI 75.070 € (+1,78 %)     ASML HOLDING 1 578.200 € (-0,99 %)     BOLLORE 4.100 € (+0,15 %)     VEOLIA ENVIRON. 36.230 € (+0,22 %)     SMCP 5.015 € (+0,30 %)     FLOW TRADERS 25.580 € (-0,93 %)     ASM INTERNATIONAL 948.000 € (-4,34 %)     AYVENS 11.460 € (-0,87 %)     CSG 12.682 € (+2,69 %)     BE SEMICONDUCTOR 282.700 € (-2,21 %)     SCOR SE 31.980 € (+0,50 %)     STMICROELECTRONICS 62.580 € (-3,81 %)     ESSILORLUXOTTICA 168.650 € (+1,54 %)     CRCAM TOURAINE CCI 138.500 € (-0,93 %)     LISI 66.100 € (-0,15 %)     LVMH 495.750 € (+0,27 %)     BOUYGUES 49.750 € (-0,78 %)     DSM FIRMENICH AG 79.980 € (-0,65 %)     NEXANS 141.100 € (-3,75 %)     STELLANTIS NV 5.024 € (-1,95 %)     THALES 216.500 € (-0,87 %)     UMG 18.355 € (+0,71 %)     NN GROUP 76.320 € (-0,29 %)     AHOLD DEL 35.430 € (+0,85 %)     2CRSI 27.520 € (+8,01 %)     SODEXO 51.250 € (-0,10 %)     SOITEC 114.350 € (+1,87 %)     TKH GROUP 43.620 € (+1,73 %)     LNA SANTE 34.000 € (+3,03 %)     OVH 13.600 € (+1,49 %)     BAM GROEP KON 12.550 € (-1,18 %)     AMG 32.900 € (-1,56 %)     EUROFINS SCIENT. 68.960 € (+1,00 %)     CEGEDIM 11.040 € (-1,43 %)     AALBERTS NV 38.980 € (-1,66 %)     DANONE 72.120 € (+3,06 %)     ALSTOM 15.380 € (-1,94 %)     REXEL 36.860 € (-1,18 %)     RELX 27.440 € (-0,29 %)     HAFFNER ENERGY 0.217 € (-2,25 %)     ERAMET 45.160 € (-1,40 %)     SAINT GOBAIN 80.600 € (-1,42 %)     BNP PARIBAS ACT.A 101.120 € (-1,83 %)     RUBIS 31.540 € (+0,64 %)     JCDECAUX 19.050 € (+1,33 %)     PERNOD RICARD 65.960 € (-0,06 %)     SAVENCIA 66.600 € (0,00 %)     AIRBUS 191.900 € (-1,63 %)     ALTEN 53.400 € (+1,81 %)  
News Réglementées
10/01/2023 12:30

Empower Clinics Subsidiary Wins Laboratory Services Agreement with European Medical Products Manufacturer

MediSure Laboratory to offer clinical study services for client expansion to US market

VANCOUVER, BC / ACCESSWIRE / January 10, 2023 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory - today announced that MediSure Laboratory signed a laboratory services agreement with Alp MedTech AG ("ALP"), the authorized representative of Atlas Medical Gmbh ("Atlas").

This agreement follows the partnership announced on December 19th between Empower and ALP - the authorized representative of Atlas, a European medical device company specializing in the distribution and manufacturing of invitro diagnostic tests and medical devices. Atlas was founded in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and kits. With a presence in more than 80 countries worldwide, their product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry.

Empower anticipates it will generate new accretive service revenue from the provision of ongoing clinical study services. This also accelerates the introduction of new medical devices and test products for distribution by Empower into the US market.

"This is another accretive deal with a focus on the US market that follows the announcement of a strategic partnership agreement signed last month", stated Steven McAuley, Chairman and CEO of Empower Clinics "ALP clearly sees the value of MediSure Labs to help them perform the clinical studies in Dallas that are required for US government Food and Drug Administration 510K approvals for the sale of Atlas equipment in the US market. With Dallas as a major healthcare hub in the US, MediSure Lab has both the medical equipment, expertise, and the network of health professionals to help ALP and Atlas to enter the US market efficiently and rapidly.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company with multi-disciplinary clinics, an at-home medical testing device company and state-of-the-art medical diagnostics laboratories. With a growing presence in the U.S. and Canada. Empower is a leader in integrated healthcare and diagnostics solutions and is reshaping the model for patient-first wellness.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:

Steven McAuley CEO
s.mcauley@empowerclinics.com
+1 855-855-9058

Investors:

Tamara Mason

Business Development & Communications
t.mason@empowerclinics.com
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding it will generate new accretive service revenue from the provision of ongoing clinical study services, plus it accelerates bringing to U.S. markets new medical devices and test products for distribution by Empower. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: Empower Clinics Inc.



View source version on accesswire.com:
https://www.accesswire.com/734643/Empower-Clinics-Subsidiary-Wins-Laboratory-Services-Agreement-with-European-Medical-Products-Manufacturer

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière